Sunday Edition: Horses as Food

Key Takeaways

• 105,000 horses were slaughtered in 2005, primarily for export
• 2025 horse exports generated $366 million, led by Japan and Canada
• Phenylbutazone drug residues block EU approval of U.S. horse meat
• No federal ban, but lack of USDA inspection stops domestic sales

Pulse Analysis

The disappearance of USDA‑inspected horse‑slaughter plants in 2006 was not driven by a direct prohibition but by a budgetary decision that cut funding for inspectors. That move instantly collapsed the domestic supply chain, forcing the remaining facilities—Dallas Crown, Beltex, and Cavel International—to shut within a year. While horse meat remains legal to consume, the absence of a regulated processing environment means consumers cannot purchase traceable, safe products in the United States, effectively turning the market into a de‑facto ban.

Export dynamics have taken on greater importance as the U.S. pivots to selling live horses abroad. In 2025, horse‑related trade reached $366 million, with Japan, Canada, Ireland, Mexico and the United Kingdom as top buyers. However, the European Union’s stringent drug‑record requirements, especially concerning phenylbutazone—a painkiller banned in food animals—have kept U.S. horse meat off European tables. Without comprehensive medication histories, the European Food Safety Authority flags the product as a food‑chain risk, limiting market access and reinforcing the reliance on live‑animal exports.

Future policy shifts could cement the current impasse. The annual USDA budget proviso that bars spending on horse‑slaughter inspection may be replaced by a permanent statutory ban, eliminating any window for domestic processing. This would preserve the status quo, maintaining the United States as a net exporter of live horses while keeping horse meat out of the American food supply. Stakeholders—ranchers, exporters, and animal‑welfare advocates—must navigate a landscape where food safety, ethical concerns, and trade regulations intersect, shaping the long‑term viability of the equine industry.